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ABSTRACT
2-Methoxyestradiol (2-ME) is a physiological metabolite of 17β-estradiol. At 
pharmacological concentrations, 2-ME inhibits colon, breast and lung cancer in tumor 
models. Here we investigated the effect of physiologically relevant concentrations 
of 2-ME in osteosarcoma cell model. We demonstrated that 2-ME increased nuclear 
localization of neuronal nitric oxide synthase, resulting in nitro-oxidative DNA 
damage. This in turn caused cell cycle arrest and apoptosis in osteosarcoma cells. 
We suggest that 2-ME is a naturally occurring hormone with potential anti-cancer 
properties.
INTRODUCTION
2-Methoxyestradiol (2-ME) is a physiological 
metabolite of 17β-estradiol (E2). It is synthesized through 
the hydroxylation and O-methylation of E2 at the 2-position 
[1, 2]. Serum levels of 2-ME range from 3 × 10−11 M in men 
to as much as over 3 × 10−8 M in pregnant women [3–6]. 
Pharmacological concentrations of 2-ME (10−7 – 10−5 M) 
inhibit cancer in various experimental models. In vitro and 
in vivo models revealed that 2-ME inhibited growth of colon 
[7], breast [8, 9], lung [10] cancer as well as endothelial cells 
[11, 12]. 2-ME (branded as Panzem) is currently recognized 
as a potent inhibitor of angiogenesis and tumor growth [7, 
13–17]. Recommended oral dose of 2-ME is 1000 mg, 
4 times a day [14]. Treatment with 2-ME NanoCrystal 
dispersion enhanced clinical benefit rate due to the 
improved bioavaibility of the compound and is preferably 
used in clinical practice [14, 15]. Steady-state Cmax 
plasma concentration of 2-ME reached a pharmacological 
concentration of 2.17 × 10−7 M. The minimum estimated 
target concentration of 2-ME is 1.1 × 10−8 M, which is 
considered as a high physiological concentration [13, 14]. 
Multiple clinical trials have used 2-ME as an efficient 
therapeutic agent for several types of cancer [7, 13–17]. 
In contrast, there are only a few studies concerning the 
physiological activity of 2-ME [5, 6, 53]. In spite of its 
proven anticancer activity, the molecular mechanisms 
of 2-ME remain unclear. Preclinical studies suggest that 
2-ME directly inhibits angiogenesis and induces apoptosis 
in tumorous and rapidly proliferating cells. 2-ME induces 
both extrinsic and intrinsic apoptotic pathways associated 
with the overexpression of p53 [18, 19, 20]. Additionally, it 
takes part in stress-induced apoptosis due to the generation 
of reactive oxygen (ROS) and nitrogen (RNS) species 
[21–23]. Our previous study demonstrated that the anticancer 
effects of 2-ME are associated with the selective increase 
in neuronal nitric oxide synthase (nNOS) within highly 
metastatic osteosarcoma (OS) 143B cells [21]. In 2002, Su 
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and co-workers reported that microtubule-disturbing agents, 
including 2-ME, modify NO generation [24]. Nitric oxide 
synthases (NOSs) are a group of hemoproteins that catalyze 
the oxidation of L-arginine to citrulline, releasing a molecule 
of nitric oxide NO (II) [25]. At least 3 isoforms of NOS have 
been distinguished: neuronal nitric oxide synthase (nNOS, 
NOS 1, NOS I), found mainly in neurons; inducible nitric 
oxide synthase (iNOS, NOS 2, NOS II), induced by factors 
such as stress or inflammation; and endothelial nitric oxide 
synthase (eNOS, NOS 3, NOS III), expressed mainly in 
endothelial cells [25]. The regulatory mechanisms controlling 
the expression and localization of nNOS are very complex. 
Though nNOS is usually found within the cytosol, it may be 
also recruited to the nucleus [26, 27, 28]. The reasons for the 
nuclear recruitment of nNOS remain unclear.
In our study, we investigated the anticancer effects 
of 2-ME at physiologically and pharmacologically relevant 
concentrations in osteosarcoma (OS) cell models. OS is 
one of the most common bone cancers of childhood and 
adolescence. It is characterized by the formation of immature 
bone structures or osteoid tissue by cancerous cells [29, 
30, 31]. In the light of many studies, 2-ME can become a 
potent and relatively safe treatment for OS patients [19, 32, 
33, 34, 35]. Here, we showed that the anticancer properties 
of 2-ME may be explained by DNA damage caused by 
generation of nitric oxide (NO). 2-ME increased nuclear 
localization of nNOS in OS cells, possibly causing nuclear NO 
production. Thus, 2-ME could be considered as a naturally 
occurring hormone of potential oncostatic properties.
RESULTS
Effect of physiological and pharmacological 
relevant concentrations of 2-ME on OS 143B 
cell death
Our first goal was to determine the influence of 
physiological (10−12 M – 10−8 M) and pharmacological 
(10−7 M – 10−5 M) relevant concentrations of 2-ME on 
induction of cell death within 143B OS cells. These 
concentrations were determined from the available 
literature data [3–6, 19, 21, 33, 42–47]. Previously, we 
demonstrated that 2-ME inhibited cell growth and induced 
cell death in hippocampal (HT22) and OS (143B) cell 
lines at high pharmacological concentrations [21]. Herein, 
the cells were treated with different concentrations (10−12 
M – 10−5 M) of 2-ME for 24 h. Induction of apoptosis 
and necrosis was determined by flow cytometry. 2-ME 
induced apoptosis in 143B OS cells not only at tested 
pharmacological relevant concentrations (10−7 M – 10−5 M), 
but also at physiological concentrations (10−10 M – 10−8 M) 
(Figure 1A). At least 10% of apoptotic 143B cells 
were observed in the presence of 2-ME ranging from 
concentrations of 10−10 M to 10−6 M. While, treatment of 
143B OS with 10−5 M 2-ME resulted in a dramatic 40% 
increase in apoptotic cell number in comparison to the 
control (Figure 1A). Surprisingly, we did not observe 
any induction of necrosis by physiological relevant 
concentrations of 2-ME (Figure 1B). Necrosis of 143B OS 
Figure 1: Induction of cell death and inhibition of cell cycle of 143B cells by 2-ME. Induction of apoptosis A. and necrosis 
B. by 2-ME. 143B OS cells were treated with different concentrations of 2-ME (10−12 M - 10−5 M) for 24 h. The cells were then harvested 
and the percentage of apoptotic and necrotic cells was determined by Annexin V-PI staining. Values are the mean ± SE of three independent 
experiments (N = 6 replicate cultures). The absence of an error bar denotes a line thickness greater than the error. *P < 0.01, **P < 0.001, 
***P < 0.0001, ****P < 0.00001 versus control cells (C). C. Cell cycle analysis in 143B OS cells treated with 2-ME. After a 24 h treatment 
with 2-ME (10−8 M – 10−6 M), the cell cycle arrest was determined using the In Cell Analyzer 2000. The cells were stained with a mixture 
of Hoechst 33342 and Cell TraceTM Calcein Red-Orange. Each experiment was performed at least three times.
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cells was observed only under pharmacological relevant 
concentrations (10−6 M and 10−5 M) of 2-ME (Figure 1B). 
This is consistent with our previous study [21].
Effect of physiological and pharmacological 
relevant concentrations of 2-ME on the 
inhibition of the 143B OS cell cycle
Previously, our research group demonstrated 
that 2-ME-induced cell cycle arrest in 143B cells was 
concentration-dependent [43]. Since physiological and 
pharmacological relevant concentrations of 2-ME exerted 
anticancer effects in previous experiments, current 
studies were performed with the selected, representative 
concentrations: physiological (10−8 M) and pharmacological 
(10−7 M, 10−6 M) (Figure 1C). Cell cycle analysis was 
conducted by imaging cytometry and cells were stained 
with Hoechst 33342 and Cell TraceTM Calcein Red-Orange. 
The number of 143B OS cells within the G2 and M phases 
of the cell cycle increased with a 24 h treatment of every 
2-ME concentration (Figure 1C). After 24 h incubation 
with 10−8 M, 10−7 M, and 10−6 M of 2-ME, 22.16%, 30.15% 
and 31.53% of the OS cells were in the G2 and M phases, 
respectively as compared with the control (16.38%). Taken 
together, 2-ME may also be considered as a physiological 
oncostatic agent regulating cell proliferation and death.
Potential mechanisms of 143B OS cell death 
induced by 2-ME
In our previous study, we demonstrated that 2-ME 
under high pharmacological relevant concentrations 
selectively increased nNOS level within 143B OS and 
HT22 hippocampal cells, resulting in cell death [21]. 
The maximal nNOS expression peaked between 6 h 
and 8 h of incubation. Moreover, specific inhibitor of 
nNOS reversed cell death. E2 (10−6 M, 10−5 M) did not 
significantly affect nNOS protein levels [21]. Thus, 
this mode of action seems to be unique for 2-ME, since 
E2 did not elicit any effects on nNOS concentrations 
[21]. Similar effects were found at physiological 
concentrations of 2-ME (Figure 2).
In the current study, nNOSα expression was 
analyzed by Western blotting using specific anti-nNOS 
antibodies (Figure 2D). nNOSα was reported as an 
isoform that may be recruited to the nucleus [26, 27, 28]. 
As presented, total level of nNOSα increased after 1 h of 
incubation with 10−9 M to 10−5 M of 2-ME (Figure 2D). 
Precisely, nNOSα increased 2-fold after incubation with 
10−7 M to 10−5 M of 2-ME. Incubation with 10−8 M and 
10−9 M of 2-ME altered nNOSα expression 1.84 and 1.64 
times, respectively. Immunofluorescence microscopy and 
imaging cytometry was used to analyze the intracellular 
localization of nNOS in 143B OS cells. Physiological 
(10−8 M) and pharmacological (10−7 M, and 10−6 M) 
concentrations of 2-ME were used. We observed that 
nuclear fraction of nNOS was elevated after stimulation 
with all used concentrations of 2-ME (Figure 2A–2C). 
Significant increases were observed in the level of nNOS 
in nuclei of 143B cells after 2 h and 6 h of incubation 
with 10−8 M 2-ME. Treatment with pharmacological 
relevant concentrations (10−7 M, and 10−6 M) resulted 
in nuclear nNOS localization after 6 h and 8 h of 
incubation (Figure 2A). These data are in agreement 
with the observed increase in the total level of nNOSα 
(Figure 2C). Inhibition of 143B OS cell growth by 10−6 
M of 2-ME was significantly reversed after adding 
L-NDBA, an nNOS inhibitor (Nω-Nitroarginine-2,4-L-
diaminobutyric amide di(trifluoroacetate) salt 10−5 M) 
(Figure 2E).
Nitro-oxidative stress level after stimulation 
with 2-ME
Previously, we demonstrated using flow cytometry 
and 4,5-diaminofluorescein diacetate (DAF-2DA) 
indicator that incubation of HT22 hippocampal and 
143B OS cells with 10−6 M 2-ME resulted in an increase 
in NO levels due to the upregulation of nNOS [21]. 
Herein, NO production was measured after treatment 
of 143B cells with physiological and pharmacological 
relevant concentrations of 2-ME. Imaging cytometry and 
specific fluorescent indicators were used to determine 
the NO level in live cells. 4-amino-5-methylamino-2′, 
7′-difluorofluorescein diacetate (DAF-FM DA) was 
chosen as the indicator because it is more sensitive to 
NO, more photo-stable and less pH sensitive than DAF-
2DA [63, 64]. A significant increase in the level of NO 
was observed in a time-dependent manner (Figure 3A). 
After 2 h of incubation with 10−8 M, 10−7 M, and 10−6 M 
of 2-ME, the level of NO was only slightly augmented 
by 3.4%, 1%, 5.5% in comparison to the control, 
respectively (Figure 3A). NO level significantly increased 
by 24%, 27%, 39% after 6 h of treatment with 10−8 M, 
10−7 M, 10−6 of 2-ME, respectively (Figure 3A, 3C). 
Interestingly, after 8 h of incubation, an increase in 
NO levels was detected only after treatment with 10−8 
M and 10−7 M of 2-ME (Figure 3A, 3C). A 2-ME-
mediated increase in the level of NO was observed 
without the presence of the nNOS inhibitor, L-NDBA. As 
demonstrated in Figure 3B, level of NO was increased 
by 10−6 M 2-ME and then significantly decreased after 
preincubation with 10−5 M L-NDBA. Induction of nitro-
oxidative stress determined by 2′,7′-dichloro-fluorescein 
diacetate (DCF-DA) fluorescence by 10−6 M 2-ME was 
also reversed by using another specific nNOS inhibitor, 
4-AAPNT (N-[(4S)-4-amino-5-[(2-aminoethyl)amino]
pentyl]-N′-nitroguanidine tris(trifluoroacetate), 10−5 M) 
(Figure 3D). These results confirmed the involvement of 
nNOS in the anticancer mechanisms of action of 2-ME. 
Increased expression of nNOS was correlated with 
enhanced production of NO (Figure 2A, 2C).
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2-ME-induced DNA damage
We were wondering whether 2-ME increased nNOS 
levels and nitro-oxidative stress generation within the 
nuclei of 143B OS cells may exert any effects on DNA 
damage and genomic instability In a previous study, the 
nNOS inhibitor, L-NDBA, significantly decreased the DNA 
fragmentation rate after 16 h of incubation with 10−6 M of 
2-ME [21 and Figure 5B]. Due to the fact that we observed 
nNOS induction after 1 h maintaining till 8 h of incubation 
with both physiological and pharmacological concentrations 
of 2-ME (Figure 2C), we assessed DNA strand breaks after 
2 h and 8 h of incubation with 2-ME. Two versions of the 
comet assay were used to evaluate DNA damage. The alkaline 
assay detected single strand breaks (SSBs) and the neutral 
assay detected double strand breaks (DSBs) [39]. Time- and 
2-ME-concentration-dependent increases in both SSBs 
and DSBs were observed (Figure 4). We present that 2-ME 
increased DNA damage as soon as after 2 h of incubation 
with the stimuli what is in the correlation with increased total 
nNOS level (Figure 2). DSBs were 1.37, 1.37, and 1.92 times 
greater in number after 2 h of incubation with 10−8 M, 10−7 
M, and 10−6 M of 2-ME in comparison to the control (0.82), 
respectively (Figure 4A). Incubation with 10−8 M, 10−7 M, 
and 10−6 M of 2-ME for 2 h resulted in 5.30-, 7.72-, and 11.45- 
fold increases in the SSBs in comparison to the control (1.86), 
Figure 2: 2-ME results in nuclear localization of nNOS in OS 143B cells. A. 143B OS cells were treated with 10−6 M of 2-ME for 
8 h. nNOS levels were evaluated by immunofluorescence microscopy. The cells were incubated with a mouse monoclonal antibody against 
nNOS and a FITC-conjugated, secondary polyclonal rat antibody against mouse IgG (green). Nuclei were visualized with Hoechst 33342 
(blue). The representative images are shown. B. 143B OS cells were treated with 10−6 M of 2-ME for 8 h. Nuclear and cytosolic fractions 
of nNOS increased by 2-ME were determined by Western blotting. The representative images are shown. C. The quantification analysis of 
nuclear nNOS levels by imaging cytometry. The fluorescence density is presented in RFUs. For nNOS immunostaining, interphase nuclei 
were used. After 2-, 6-, 8-h treatments with 2-ME (10−8 M - 10−6 M), 143B OS cells were fixed, then incubated with antibodies (A) The 
fluorescent signals were captured with an In Cell Analyzer 2000 (GE Healthcare, UK) equipped with a high performance CCD camera. 
Values are the mean ± SE of three independent experiments (N = 6 replicate cultures). The absence of an error bar denotes a line thickness 
greater than the error. *P < 0.01, **P < 0.001, ***P < 0.0001, ****P < 0.00001 versus control cells (C). D. 1 h treatment of 143B OS cells 
with 2-ME (10−9 M -10−5 M) resulted in an increase of the total level of nNOSα. The result was obtained by Western blotting using nNOS 
specific antibodies. The band corresponding to nNOS alpha was analyzed. The representative data are shown. E. 10−5 M L-NDBA reversed 
2-ME-induced inhibition of 143B OS cell growth. Values are the mean ± SE of three independent experiments (N = 6 replicate cultures). 
The absence of an error bar denotes a line thickness greater than the error. *P < 0.01, **P < 0.001, ***P < 0.0001, ****P < 0.00001 versus 
control cells (C) Each experiment was performed at least three times.
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respectively (Figure 4B, 4C). The number of DSBs and SSBs 
subsequently increased after 8 h of incubation with 2-ME. In 
comparison to the control (1.31), 3.23-, 4.66-, and 3.25-fold 
increases were observed in DSBs after 143B OS cells were 
incubated with 10−8 M, 10−7 M, and 10−6 M of 2-ME for 8 
h, respectively (Figure 4A, 4C). SSBs increased by a factor 
of 7.02, 5.14, and 12.85 after 8 h of incubation with 10−8 M, 
10−7 M, and 10−6 M of 2-ME in comparison to the control 
(4.18), respectively (Figure 4B, 4C). Appearance of SSBs and 
DSBs after 2 h of incubation with 2-ME seemed to be one 
of the first signals of DNA damage. The cytokinesis-block 
micronucleus (CBMN) assay confirmed that 2-ME stimulated 
genotoxicity in 143B OS cells. Micronuclei formation is 
correlated with altered genomic stability. Genomic instability 
is often associated with cancer and may be indicative of a poor 
prognosis for some types of cancer [74, 75, 76, 77]. By imaging 
cytometry the influence of 2-ME on micronucleus formation 
was examined. Our experimental data suggested that a time 
period of 24 h was sufficient for the effective cell division and 
micronucleus formation of 143B OS cells. 24 h treatment with 
physiological and pharmacological relevant concentrations of 
2-ME lead to increased genomic instability within the 143B 
cells. This confirmed the genotoxic effects of 2-ME within 
the experimental model. Incubation with 2-ME resulted in 
an increased amount of micronuclei that was concentration-
dependent. After 24 h of incubation with 10−8 M, 10−7 M, and 
10−6 M of 2-ME, micronucleus formation increased by 23.4% 
± 1.5, 25.3% ± 1.4, and 28% ± 1.1 in comparison to the control 
Figure 3: Induction of nitro-oxidative stress by 2-ME. A. NO production increased by 2-ME after 2-, 6-, 8-h treatments with 
2-ME (10−8 M - 10−6 M). NO levels were evaluated by imaging cytometry using fluorogenic probes, DAF-FM DA (5x10−6 M), and a 
10-min incubation time in PBS buffer. The fluorescent signals were captured with an In Cell Analyzer 2000 (GE Healthcare, UK) equipped 
with a high performance CCD camera. The fluorescence density is presented in RFUs. Values are the mean ± SE of three independent 
experiments (N = 6 replicate cultures). The absence of an error bar denotes a line thickness greater than the error. *P < 0.01, **P < 0.001, 
***P < 0.0001, ****P < 0.00001 versus control cells (C). B. NO production induced by 2 h incubation with 10−6 M of 2-ME was reversed 
by specific nNOS inhibitor, L-NDBA (10−5 M). C. Representative images of induction of NO by 2-ME determined by imaging cytometry 
(A) Cell nuclei are shown in blue and the nitric oxide levels in green. The fluorescent signals were captured with an In Cell Analyzer 2000 
(GE Healthcare, UK) equipped with a high performance CCD camera. D. Nitro-oxidative stress induced by an 8 h incubation with 10−6 
M of 2-ME was reversed by specific nNOS inhibitor, 4-AAPNT (10−5 M). Values are the mean ± SE of three independent experiments 
(N = 6 replicate cultures). The absence of an error bar denotes a line thickness greater than the error. *P < 0.01, **P < 0.001, ***P < 0.0001, 
****P < 0.00001 versus control cells (C) Each experiment was performed at least three times.
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(20.35% ± 1), respectively (Figure 5A, 5B). Activation of the 
DNA damage response (DDR) is an important determinant of 
cell sensitivity to chemotherapeutic drugs eliminating tumor 
cells. 53BP1 is a protein recognizing the central DNA-binding 
domain of p53. It relocates to the sites of DNA strand breaks 
in response to DNA damage [39]. We investigated whether 
the DNA damage response was activated after the treatment 
of OS cells with 2-ME at physiological and pharmacological 
concentrations. DNA damage detected as 53BP1 foci/nucleus 
was evaluated by means of imaging cytometry. As demonstrated 
in Figure 5, recruitment of 53BP1 was significantly increased 
after 2 h of treatment at all concentrations of 2-ME (Figure 5C, 
5D). The recorded data fully supported the observed SSBs and 
DSBs in 143B OS cells after treatment with 2-ME (Figure 4). 
The cells in which DDR was activated may be those that did 
not undergo cell death, another will be transferred to the way 
of cell death [78].
DISCUSSION
Herein, we demonstrated a new mode of anticancer 
action of 2-ME at physiological and pharmacologically 
relevant concentrations. Increased levels of nNOS within 
the nuclei of 143B OS cells and the subsequent induction 
of nitro-oxidative stress caused cell cycle arrest and 
cancer cell death. We used the OS experimental model 
due to its high malignancy, chemoresistance and genomic 
instability [101].
Various preclinical and clinical cancer models 
proved the anticancer properties of 2-ME [13, 14, 15, 
48, 49, 50, 51, 52], though there are only few reports 
concerning the physiological activity of 2-ME [5, 6, 
53]. Similarly to our current results, Vijayanathan and 
co-workers demonstrated the inhibitory effects of 10−8 
M of 2-ME towards MCF-7 cell growth [5]. Decreased 
concentrations of 2-ME have been implicated as one of 
the reasons for pre-eclampsia, suggesting that 2-ME 
plays an important physiological role [6]. For the first 
time, we managed to prove that at physiological 2-ME 
concentrations (10−10 M – 10−8 M) induced apoptosis 
in highly metastatic 143B OS cells. While high 
pharmacological relevant 2-ME concentrations (10−6 M – 
10−5 M) induced necrosis. Little information is available 
concerning the induction of necrosis within cancer cells 
by 2-ME. High pharmacological concentrations of 2-ME 
induced necrosis within human endometrial carcinoma 
cells (RL-95–2) [44]. Up to date, 2-ME was shown to 
inhibit cell growth and induce apoptosis or cell death in 
cancer cells [19, 21, 33, 35, 45, 54–56].
Previously, we demonstrated that high pharma-
cological concentrations of 2-ME lead to OS and 
hippocampal cell death through the induction of nNOS 
[21]. In the current study, we hypothesize that, under 
physiological and therapeutical conditions, 2-ME stimulates 
the nuclear hijacking of nNOS and directly induced nitro-
oxidative stress within the nucleus. 2-ME seems to be strictly 
Figure 4: 2-ME induced DNA damage at physiological and pharmacological relevant concentrations. A, B. DSBs and SSBs 
after 2- and 8-hour treatments with 2-ME (10−8 M - 10−6 M) determined by (pH = 10) and alkaline (pH > 12) comet assay, respectively. The 
tail moment was considered a general parameter to the DNA integrity assessment. Values are the mean ± SE of three independent experiments. 
100 single cells were taken into analysis of DNA damage. The absence of an error bar denotes a line thickness greater than the error.  
*P < 0.01, **P < 0.001, ***P < 0.0001, ****P < 0.00001 versus control (C). C. DNA damage measurements at neutral and alkaline pH after 
a 2 h treatment with 2-ME (10−8 M - 10−6 M). The representative images are shown. Each experiment was performed at least three times.
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associated with pro-apoptotic and oncostatic mechanisms of 
action. nNOS has been believed to be a cytosolic isoform 
[57, 58]. However, different splicing variants and subcellular 
localizations of the enzyme were recently reported [26]. 
Nonetheless, the exact role of nNOS within the nucleus has 
continued to remain undefined [26, 27, 59]. The effect of 
2-ME on proteins regulating nNOS translocation from the 
cytosol to the nucleus is currently under our investigation. 
In contrast to eNOS or iNOS, nNOS is a larger protein 
containing a PDZ domain at its N-terminal, a consensus 
sequence of approximately 90 amino acids [60–62]. 
The PDZ domain seems to be an important factor for the 
facilitation of nNOS to distinct intercellular compartments 
[27, 59]. Aquilano and colleagues demonstrated that PDZ is 
essential for the nuclear recruitment of nNOS, thus favoring 
NO production [26]. 2-ME-increased nitro-oxidative stress 
associated with the generation of NO and/or its derivatives 
within the nuclei of OS cells may have directly resulted in 
SSBs and DSBs, leading to 143B OS cell death. The link 
between nuclear proteotoxic stress and cancer cell death 
has been recently reported [79, 80, 81]. Local generation 
of NO and/or their reactive derivatives (nitrogen dioxide, 
peroxynitrite) are likely contributed to DNA damage 
[82, 83, 84]. In vitro studies with cellular models indicated 
that NO and its derivatives were able to induce direct- and 
mediated-genotoxic effects [85, 86]. Bossy-Wetzel and 
Lipton reported that excessive amounts of NO may have 
induced S-nitrosylation and/or triggered DNA damage, 
resulting in cell death [87]. ROS/RNS action on DNA 
may have caused several modifications of nucleotides and 
generated SSBs and DSBs [82, 84, 88]. Oxidative stress 
preferentially induced micronucleus formation and mediated 
the genomic instability caused by p53 dysfunction [89]. 
Diverse chemotherapeutics like 2-ME may be selectively 
toxic to tumor cells by increasing oxidative/nitro-oxidative 
stress and pushing the already-stressed cancer cells beyond 
their limit [90, 91]. DNA damage caused by increased 
nNOS levels within OS cell nuclei led to cancer cell death 
at physiological and pharmacological concentrations of 
2-ME. Consistent with our study, 2-ME was reported to 
enhance the sensitivity of glioma cell lines to radiotherapy 
by arresting the cell cycle at the G2/M phase and increased 
DNA damage [92]. Khoei and colleagues demonstrated that 
combined treatment with 25 × 10−5 M of 2-ME and 60Co 
significantly increased iododeoxyuridine DNA damage. 
Only slight DNA damage was observed when 2-ME was 
Figure 5: 2-ME induced genomic instability and DNA repair at physiological and pharmacological relevant 
concentrations. A, B. Micronuclei formation after the 24 h treatment with 2-ME (10−8 M - 10−6 M ) determined by CBMN assay using 
imaging cytometry. Arrowheads indicate micronuclei. C, D. 143B OS cells were treated with 2-ME (10−8 M - 10−6 M ) for 2, 8, 24 h and 2-ME 
stimulated DNA repair by increasing 53BP1 foci/nucleus (green) was investigated. Nuclei were visualized using Hoechst 33342 staining 
(blue). Values are the mean ± SE of three independent experiments (N = 6 replicate cultures). 500 single cells were taken into analysis of DNA 
damage and DDR. The representative images are shown (B, D). The absence of an error bar denotes a line thickness greater than the error.  
*P < 0.01, **P < 0.001, ***P < 0.0001, ****P < 0.00001 versus control (C). Each experiment was performed at least three times.
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administered separately [93]. This result may be attributable 
to the U87MG glioblastoma cancer cell line spheroid model. 
Higher resistance has been observed within spheroid cultures 
in comparison to monolayer cultures [93, 94]. Moreover, 
cancer cell chemosensitization by NO during anticancer 
therapy has been reported [95]. Treatments of human cancer 
cells with NO and NO mimetics also have been shown to 
restore chemoresistance both in vivo and in vitro [96, 97, 
98, 99]. On the other hand, malfunction of DNA damage 
repair system may result in chemoresistance of cancer cells 
and further cancer progression [75, 78, 100]. It may be 
considered as one of the limitations of long-term 2-ME use.
In conclusion, we demonstrated that SSBs and DSBs 
is involved in the 2-ME oncostatic mechanism (Figure 6). 
Anticancer effects were observed at physiological and 
pharmacologically relevant concentrations. Mechanisms 
of nuclear transport of nNOS induced by 2-ME need to be 
further investigated.
MATERIALS AND METHODS
Cell line and culture conditions
143B OS cell line was obtained from the American 
Tissue Type Collection (ATTC-8303). Cells were cultured 
at 37oC in a humidified atmosphere and saturated with 
5% CO2. Dulbecco’s Modified Eagle’s Medium was 
supplemented with 10% heat-inactivated fetal bovine serum 
and a penicillin (100 μg/mL)/streptomycin (100 μg/mL) 
cocktail (Sigma-Aldrich, Poland).
Cell treatment
The 143B OS cells were treated with various 
concentrations of 2-ME and time, depending on the design 
of experiments. 10−5 M of nNOS inhibitor (4-AAPNT, 
L-NDBA) was added to the cells after 2 h of pre-treatment. 
Figure 6: 2-ME induces OS cell death via increasing nuclear nNOS resulting in DNA damage and genomic instability. 
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The medium was removed and the cells were washed with 
a phosphate-buffered saline (PBS, Sigma Aldrich). A new 
medium containing 2-ME replaced the previous one. We used 
charcoal-stripped FBS (Sigma Aldrich, Poland) in the medium 
for cell treatment. Charcoal-stripped FBS is used to elucidate 
the effects of hormones in a variety of in vitro systems.
Reagents
Tissue culture media, antibiotic cocktail, fetal bovine 
sera, 2-ME, the nNOS inhibitors L-NDBA, 4-AAPNT 
were purchased form Sigma Aldrich Poland. Anti-rabbit 
IgG were purchased from Abcam (Cambridge, UK). 
Mouse antibodies against nNOS, secondary polyclonal 
rat antibody against mouse IgG were obtained from BD 
Biosciences (Germany).
Assessment of apoptosis by flow cytometry with 
Annexin V-propidium iodide (PI) staining
The analysis was performed as previously described 
[21, 36]. 143B OS cells were seeded onto six-well plates at 
a density of 3 × 105 cells/well. After 24 h of culturing in the 
standard medium, the cells were treated with 2-ME for 24 h. 
The cells were then pelleted and incubated with Annexin 
V and PI according to manufacturer’s protocol (BD 
Pharmingen, Poland). Afterwards, the cells (3 × 104/sample) 
were analyzed and the fluorescent signals of Annexin V 
conjugate and PI were detected at the fluorescence intensity 
channels FL1 and FL3 (BD FACScan). The results were 
then analyzed by Cyflogic software, version 1.2.1. Each 
experiment was performed at least three times.
Cell cycle analysis
After treatment with 2-ME, 143B OS cells were 
stained with a mixture of Hoechst 33342 (2.5 μg/ml) and 
Cell TraceTM Calcein Red-Orange AM (2.5 × 10−6 M) (Life 
Technologies, Poland) in a serum-free DMEM medium 
at 37oC for 30 min. The OS cells were rinsed with PBS 
and subjected to cell cycle analysis using an In Cell 
Analyzer 2000 (GE Healthcare, UK) equipped with a high 
performance CCD camera.
Assessment of nitro-oxidative stress by flow 
cytometry
ROS and RNS production were determined using 
flow cytometry with DCF-DA staining. The cells were 
seeded onto six-well plates at a density of 3 × 105 cells/
well. After 24 h of culturing in the normal growth medium, 
cells were exposed to treatment with 2-ME for 24 hours. 
Subsequently, 30 min before the end of the incubation 
time, a solution of DCF-DA was added to each well of 
treated cells in order to obtain the final concentration of 
10−5 M for 2-ME. Next, both floating and trypsinized cells 
were collected by centrifugation at 1200 rpm for 7 min. 
The pellet was next washed twice with PBS, followed by 
resuspension in PBS. The whole procedure was performed 
on ice. Afterward, 3 × 104 cells were analyzed by flow 
cytometry (BD FACScan) and the results were analyzed 
by Cyflogic software, version 1.2.1. Each experiment was 
performed at least three times.
NO level by imaging cytometry
Imaging of RNS production in living cells based 
on fluorescent indicators has been reported as a fast, 
sensitive and selective method [40, 41]. After 2-, 6-, 8-h 
treatments with 2-ME, NO levels were evaluated using the 
fluorogenic probe DAF-FM DA (5 × 10−6 M) and a 10-min 
incubation time in a PBS buffer. NO-specific fluorescent 
signals were captured with an In Cell Analyzer 2000 (GE 
Healthcare, UK) equipped with a high performance CCD 
camera. For NO positive control, a NO donor – MAHMA 
NONOate (10−3 M) was used.
Immunofluorescence microscopy
The immunofluorescence was performed as 
previously described [50, 21]. The 143B OS cells were 
treated with 2-ME for 8 h. Anti-nNOS (1:50 in 0.3% 
GSA, 2 h incubation, BD Biosciences) and goat anti-
mouse secondary-conjugated with CY3 (1:100, GAM 
Cy3, 1 h incubation, Jackson Immunoresearch, Suffolk, 
UK) antibodies were used. The images were analysed 
and merged employing the ImageJ software 1.44p. Each 
experiment was performed at least three times.
nNOS immunostaining by imaging cytometry
For nNOS immunostaining, interphase nuclei 
were used. After 2-, 6-, and 8-h treatments with 2-ME in 
the 96-well plate, 143B OS cells were fixed with 3.7% 
formaldehyde containing 0.1% Triton X-100 in PBS 
for 20 min. Subsequently, the cells were incubated with 
1% bovine serum albumin (BSA) in PBST (phosphate 
buffered saline containing 0.25% Triton X-100) at room 
temperature for 30 min. After washing with PBST, the 
cells were incubated with mouse monoclonal antibodies 
against nNOS (BD Biosciences, Germany) (diluted 1:50 
in PBST–BSA [PBST containing 1% BSA]) overnight at 
4oC. The next day, FITC-conjugated, secondary polyclonal 
rat antibodies against mouse IgG (BD Biosciences, 
Germany) (diluted 1:1000 in PBST–BSA) were added 
and incubated at room temperature for 1 h. Nuclei were 
visualized with Hoechst 33342. Digital cell images were 
captured with an In Cell Analyzer 2000 (GE Healthcare, 
UK) equipped with a high performance CCD camera. To 
analyze cellular nNOS content and localization, In Cell 
Analyzer software (In Cell Analyzer Investigator) was 
used. The fluorescence density was presented in relative 
fluorescence units (RFUs). As a positive control, treatment 
with 0.1 mg/ml nocodazole was used.
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53BP1 immunostaining
The analysis was performed as previously described 
[39]. For 53BP1 immunostaining, interphase nuclei were 
used. After 2-, 8- and 24-h treatments with 2-ME in 
the 96-well plate, 143B OS cells were fixed with 3.7% 
formaldehyde containing 0.1% Triton X-100 in PBS for 20 
min. Subsequently, the cells were incubated with 1% bovine 
serum albumin (BSA) in PBST (phosphate buffered saline 
containing 0.25% Triton X-100) at room temperature for 
30 min. After washing with PBST, the cells were incubated 
with a rabbit polyclonal antibody against 53BP1 (Novus 
Biologicals, Poland) (diluted 1:200 in PBST–BSA (PBST 
containing 1% BSA)) overnight at 4°C. The next day, FITC-
conjugated secondary polyclonal antibodies against rabbit 
IgG (BD Biosciences, Germany) (diluted 1:200 in PBST–
BSA) were added and incubated at room temperature for 
1 h. Nuclei were visualized with Hoechst 33342. Digital cell 
images were captured with an In Cell Analyzer 2000 (GE 
Healthcare, UK) equipped with a high performance CCD 
camera. 53BP1 foci were scored per nucleus.
Comet assay
The analysis was performed as previously described 
[39]. DNA double-strand breaks (DSBs) and DNA single-
strand breaks (SSBs) were assessed with neutral and 
alkaline single-cell microgel electrophoresis (comet assay), 
respectively. After 2- and 8-h treatments with 2-ME, 143B 
OS cells were suspended in PBS and mixed with low melting 
(LM) agarose (0.7%). The cells were fixed to agarose (LM) 
slides and lyzed with proteinase K (0.5 mg/ml) and reduced 
glutathione (2 mg/ml) in a lysis solution (1.25 M NaCl, 50 
mM EDTA, 100 mM Tris–HCl, 0.01% N-lauroylsarcosine 
sodium salt, pH 10) at 37oC for 2 h. Electrophoresis (neutral 
comet assay buffer: 100 mM Tris–HCl, 0.5 M NaCl, 1 mM 
EDTA, 0.2% DMSO, pH 10 and alkaline comet assay buffer: 
1 mM EDTA, 0.2% DMSO, 300 mM NaOH, pH > 12) was 
performed on the treated cells. The slides were then stained 
with 2.5 × 107 M YOYO-1 (Invitrogen Corporation, Grand 
Island, NY, USA) in a 2.5% DMSO and 0.5% sucrose solution. 
The cells were mounted with a coverslip and digital comet 
images were immediately captured with an Olympus BX61 
fluorescence microscope equipped with a DP72 CCD camera 
and Olympus CellF software. The CCD capture conditions 
were: exposure time 81 ms, magnification 400x. Images 
were saved as TIFF files. At least 100 comets were measured 
per each sample triplicate using AutoComet Software http://
autocomet.com/index.php (TriTek Corp). The Tail Moment 
(Tail moment=tail length x fraction of total DNA in the tail) 
was scored as general parameter to DNA integrity assessment.
Cytokinesis-block micronucleus (CBMN) assay
143B OS cells were treated with 2-ME for 24 h. 
Micronucleus generation was measured with a CBMN 
assay using the BD™ Gentest Micronucleus Assay 
Kit and following the standard protocol outlined in the 
manufacturer’s instructions. A total of 500 binucleated 
cells per well [37, 38] were scored using an In Cell 
Analyzer 2000 (GE Healthcare, UK) equipped with a high 
performance CCD camera. For a positive control, 24 h 
treatment with 100 ng/ml mitomycin C was used.
Western blotting
The cytoplasmic and nuclear fractions were separated 
using the Nuclear Extract Kit (Active Motif, France) 
according to manufacturer’s protocol. Equal amounts of 
total cell lysates were resolved by 7% SDS-PAGE. The 
membranes were then incubated with primary antibodies 
anti-nNOS (BD Biosciences) (1:1000) overnight at 4°C and 
an analysis was performed as previously described [21, 36]. 
The chemiluminescence was detected using ImageQuant 
LAS 500 (GE Healthcare). The protein level was 
quantified by densitometry technique using the Quantity 
one 4.5.2 software. The protein levels, as determined by 
chemiluminescent signal quantification, were normalized 
relative to beta-actin levels found in the samples. Each 
experiment was performed at least three times.
Statistical analysis
The results represent the mean ± SD from at least 
three independent experiments. All microscopic evaluations 
were done on randomized and coded slides. Differences 
between control samples versus 2ME-treated samples were 
assessed with one-way analysis of variance (ANOVA) with 
post hoc testing using a Dunnett’s multiple comparison test. 
A p-value of less than 0.01 was considered to correspond 
with statistical significance. Data were analyzed using 
GraphPad Prism (GraphPad Software, Inc., version 6, USA).
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diacetate, DAF-FM DA- 4-Amino-5-methylamino- 
2′,7′-difluorofluorescein diacetate, DCF-DA- 
2′,7′-dichloro-fluorescein diacetate, DDR – DNA 
damage response, DHE – dihydroethidium, DSBs - 
DNA double-strand breaks, E2 - 17β-estradiol, 
2-ME - 2-methoxyestradiol, L-NDBA - Nω-Nitroarginine-2, 
4-L-diaminobutyric amide di(trifluoroacetate) salt, OS - 
osteosarcoma, RFUs - relative fluorescence units, ROS- 
reactive oxygen species, RNS – reactive nitrogen species, 
SOD - superoxide dismutase, SSBs - DNA single-strand 
breaks.
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